MBX Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 359.09K shares, a 113.93% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 387.77K shares, a 12744.48% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 212.46K shares, a 367.27% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 15.22K shares.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 398.55K shares, a 266.78% increase from fiscal 2024.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 108.66K shares, a 56.60% decline from fiscal 2023.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 250.35K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 359.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 974.53K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 387.77K shares 10-Q · filed 2026-05-07 | 783.30K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 212.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 398.55K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 15.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 231.56K shares derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | 167.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | |
| 2025-03-31 | 3.02K shares 10-Q · filed 2025-05-12 | |
| 2024-12-31 | 45.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 108.66K shares 10-K · filed 2026-03-12 |
| 2023-12-31 | 250.35K shares 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |